Children with relapsed neuroblastoma have poor outcomes. The combination of GD2 antibodies and chemotherapy (called "chemoimmunotherapy") has shown a high response rate in this population. Chemoimmunotherapy often requires patients be admitted to the hospital, reducing quality of life for these children. This ongoing clinical trial is evaluating different infusion durations of a GD2 antibody called naxitamab together with chemotherapy to determine if this approach might be appropriate to deliver in an outpatient setting.
Fighting childhood cancer, one cup at a time.
